You just read:

Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Naïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival

News provided by

Janssen Research and Development LLC

Jun 03, 2017, 07:43 ET